• Home
  • Ministers
  • For Consumers
    • Aboriginal and Torres Strait Islander Health
    • Conditions and Diseases
    • Education and Prevention
    • Ethical Issues
    • Gene Technology
    • Health Care Homes
    • Health products and medicines
    • Public and private healthcare
    • Industrial chemicals
    • Medicare
    • Mental Health
    • National Men's and Women's Health
    • National Rural Health Commissioner
    • Norfolk Island
    • Palliative Care
    • Pharmacy
    • Primary Care
    • Regulation and Red Tape Reduction
    • Rural and Regional Health
    • Services
    • Healthier Medicare
    • Travel Health Information
  • For Health Professionals
    • Aboriginal and Torres Strait Islander Health
    • Conditions and Diseases
    • Education and Prevention
    • Ethical Issues
    • Gene Technology
    • Genomics
    • Health Provider Compliance
    • Health products and medicines
    • Health Thesaurus
    • Health Workforce
    • Public and private healthcare
    • Healthier Medicare
    • Medicare
    • My Health Record
    • National Men's and Women's Health
    • Palliative Care
    • PBS Approved Suppliers
    • Regulation and Red Tape Reduction
    • Rural and Regional Health
    • Services
    • A Strong and Sustainable Medicare
    • Travel Health Information
  • About us
  • Media Centre
  • Programs & Campaigns
    • Agreements
    • Awards
    • eHealth
    • Programs & Initiatives
    • Campaign Certification Statements
  • Resources
    • Publications
    • Research & Statistics
    • CurrentIssues
  • Ageing & Aged Care
  • You are here:
  • Home /
  • For Consumers /
  • Education and Prevention /
  • Illicit Drugs /

Clinical guidelines and procedures for the use of methadone in the maintenance treatment of opioid dependence

Section 3: Guidelines for maintenance treatment (MMT)

Page last updated: August 2003

3.1 Induction to methadone treatment

3.2 Maintenance dosing

3.3 Adjunct treatment

3.4 Takeaway doses

3.5 Missed doses and reintroduction

3.6 Cessation of methadone maintenance treatment

  • previous page
  • next page
Listen
  • Table of contents
  • Introduction
  • Section 1: Clinical pharmacology
  • Section 2: Entry into methadone treatment
    • 2.1 Entry into methadone maintenance treatment
    • 2.2 Assessment for treatment with methadone
    • 2.3 Informed consent and patient information
    • 2.4 Meeting legislative requirements
    • 2.5 Coordinated care
  • Section 3: Guidelines for maintenance treatment (MMT)
    • 3.1 Induction to methadone treatment
    • 3.2 Maintenance dosing
    • 3.3 Adjunct treatment
    • 3.4 Takeaway doses
    • 3.5 Missed doses and reintroduction
    • 3.6 Cessation of methadone maintenance treatment
  • Section 4: Common management issues
    • 4.1 Side effects
    • 4.2 Overdose
    • 4.3 Intoxicated presentations
    • 4.4 Incorrect dose administered
    • 4.5 Continued high risk drug use
    • 4.6 Analgesia and anaesthesia
    • 4.7 Diversion of methadone
    • 4.8 Pregnancy and lactation
    • 4.9 Polydrug use
    • 4.10 HIV
    • 4.11 Hepatitis B & C
    • 4.12 Psychiatric comorbidity
  • Appendices
    • Appendix 1: Possible drug interactions with methadone
    • Appendix 2: Assessment of intoxication with methadone and other drugs
    • Appendix 3: Assessment of withdrawal from commonly used drugs
    • Appendix 4: Detection time for selected drugs in urine
    • Appendix 5: Resources for patients
    • Appendix 6: Further reading and references
    • Appendix 7: Consultancy and support mechanisms

Popular

    • Feedback
    Provide feedbackIf you would like a response please complete our enquiries form.


    Comments will be used to improve web content and will not be responded to.

    Real person check

    This form uses a CAPTCHA to ensure that it is submitted by a person, instead of a machine or automated software.


    Privacy statement

    Your feedback has been submitted

    Thank you for taking the time to provide feedback. It will be used to make improvements to this website.